温州医科大学学报
溫州醫科大學學報
온주의과대학학보
Journal of Wenzhou Medical University
2015年
1期
50-54
,共5页
上皮性卵巢肿瘤%动脉介入治疗%栓塞
上皮性卵巢腫瘤%動脈介入治療%栓塞
상피성란소종류%동맥개입치료%전새
epithelial ovarian tumor%artery interventional therapy%embolism
目的：探讨动脉介入化疗栓塞在晚期上皮性卵巢癌治疗中的意义。方法：1999年12月1日至2012年5月31日在我院实施肿瘤细胞减灭术的晚期上皮性卵巢癌患者共100例，按术前是否行动脉介入化疗栓塞分为2组，即动脉介入化疗栓塞组（治疗组）和初次肿瘤细胞减灭术组（对照组）。治疗组27例，对照组73例，治疗组术前予1～2疗程动脉介入化疗栓塞后再行肿瘤细胞减灭术，对照组行初次肿瘤细胞减灭术，对其进行回顾性分析，比较2组患者临床各项指标、相关预后因素及累积生存率。结果：治疗组分级高、期别晚者所占比例高，但达到满意的肿瘤细胞减灭术者所占比例比对照组高，两者比较差异无统计学意义（P＞0.05）。多因素生存分析显示手术病理分期及手术满意度是影响患者总的生存率的独立预后因素（P=0.010及P=0.011）。治疗组3年和5年累积生存率分别为64%和48%，对照组为62%和40%，差异无统计学意义（P＞0.05）。结论：术前估计难以达到满意的肿瘤细胞减灭术的晚期上皮性卵巢癌患者，行动脉介入化疗栓塞可能提高手术的成功率，但不能提高患者总的生存率。
目的：探討動脈介入化療栓塞在晚期上皮性卵巢癌治療中的意義。方法：1999年12月1日至2012年5月31日在我院實施腫瘤細胞減滅術的晚期上皮性卵巢癌患者共100例，按術前是否行動脈介入化療栓塞分為2組，即動脈介入化療栓塞組（治療組）和初次腫瘤細胞減滅術組（對照組）。治療組27例，對照組73例，治療組術前予1～2療程動脈介入化療栓塞後再行腫瘤細胞減滅術，對照組行初次腫瘤細胞減滅術，對其進行迴顧性分析，比較2組患者臨床各項指標、相關預後因素及纍積生存率。結果：治療組分級高、期彆晚者所佔比例高，但達到滿意的腫瘤細胞減滅術者所佔比例比對照組高，兩者比較差異無統計學意義（P＞0.05）。多因素生存分析顯示手術病理分期及手術滿意度是影響患者總的生存率的獨立預後因素（P=0.010及P=0.011）。治療組3年和5年纍積生存率分彆為64%和48%，對照組為62%和40%，差異無統計學意義（P＞0.05）。結論：術前估計難以達到滿意的腫瘤細胞減滅術的晚期上皮性卵巢癌患者，行動脈介入化療栓塞可能提高手術的成功率，但不能提高患者總的生存率。
목적：탐토동맥개입화료전새재만기상피성란소암치료중적의의。방법：1999년12월1일지2012년5월31일재아원실시종류세포감멸술적만기상피성란소암환자공100례，안술전시부행동맥개입화료전새분위2조，즉동맥개입화료전새조（치료조）화초차종류세포감멸술조（대조조）。치료조27례，대조조73례，치료조술전여1～2료정동맥개입화료전새후재행종류세포감멸술，대조조행초차종류세포감멸술，대기진행회고성분석，비교2조환자림상각항지표、상관예후인소급루적생존솔。결과：치료조분급고、기별만자소점비례고，단체도만의적종류세포감멸술자소점비례비대조조고，량자비교차이무통계학의의（P＞0.05）。다인소생존분석현시수술병리분기급수술만의도시영향환자총적생존솔적독립예후인소（P=0.010급P=0.011）。치료조3년화5년루적생존솔분별위64%화48%，대조조위62%화40%，차이무통계학의의（P＞0.05）。결론：술전고계난이체도만의적종류세포감멸술적만기상피성란소암환자，행동맥개입화료전새가능제고수술적성공솔，단불능제고환자총적생존솔。
Objective: To explore the signicance of the arterial interventional chemotherapy and emboliza-tion in the treatment of advanced-stage epithelial ovarian cancer.Methods: From December 1, 1999 to May 31, 2012, 100 patients of epithelial ovarian cancer in advanced-stage were admitted and all of them had cytoreduc-tive surgery in our hospital. According to whether or not to accept the arterial interventional chemotherapy and embolization, patients of advanced-stage epithelial ovarian cancer were divided into two groups before cytore-ductive surgery. Those were the arterial interventional chemotherapy and embolization group (the treated group) and primary cytoreductive surgery group (the control group). There were 27 cases in the treated group which had 1-2 courses of the arterial interventional chemotherapy and embolization before operation. While the other 73 cases in the control group had initial cytoreductive surgery. The results were analyzed retrospectively, compar-ing the two groups of patients with clinical indicators, related prognostic factors and the cumulative survival rate. Results: Comparison of factors between the two groups showed that the treatment group with high grade, stage late accounts for the proportion to be high. However, the rates of optimal cytoreductive surgery in the treated group were higher than that of the control group. There was no statistically signiifcant difference between the two groups (P>0.05). Multivariate survival analysis showed that pathological staging and operation satisfaction were independent prognostic factors affecting overall survival rates for patients (P=0.010 andP=0.011). The 3-year and 5-year cumulative survival rates were 64% and 48% in the treated group, while 62% and 40% in the control group. There was no statistically signiifcant difference between the two groups (P>0.05).Coclusions: Patients of advanced-stage epithelial ovarian cancer who can not to achieve optimal cytoreductive surgery should receive preoperative arterial interventional chemotherapy and embolization. It may improve the success rate of the opera-tion, but can not improve the overall cumulative survival rate.
